Clinical trials: Bleeding Diathesis
Covid19, Corona Virus Infection
Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients
The purpose of this study to evaluate the translational application of the safe and effective treatment of Narrow-Band Ultraviolet light B-band (NB-UVB) to high-risk COVID-19 patients in an effort to improve their immune and…
- Conditions
- Covid19, Corona Virus Infection, Autoimmune Diseases, Coagulation Disorder, Blood
- Trial name
- NCT04818970
- Testing
- Narrow Band ultraviolet B-Band Light, non Narrow Band ultraviolet B-Band Light
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cytokind, Inc.
Maintenance Dose, Osteocalcin
Estimation of a Maintaining Daily Jarlsberg Cheese-dose
The study objective is to estimate a maintaining daily dose of Jarlsberg cheese in healthy pre-menopausal women obtaining an increase in the osteocalcin level of at least 10% after 6 weeks on maximum efficacy dose (MED) of…
- Conditions
- Maintenance Dose, Osteocalcin, Vitamin K Deficiency
- Trial name
- NCT04188080
- Testing
- Jarlsberg Cheese
- Where
- Norway
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Meddoc
Purpura, Thrombocytopenic, Idiopathic
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
The purpose of this study is to determine whether Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab prednisone are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia…
- Trial name
- Incritop (NCT01317966)
- Testing
- rhIL-11
- Where
- China
- Sponsor
- Ming Hou
Hyperfibrinolysis, Cesarean Section Complications
The Incidence of Hyperfibrinolysis During Vaginal Delivery and Cesarean Section
This study aims to find out if there are common major changes in coagulation immediately after delivery of the newborn during Cesarean (C) -section and vaginal birth.
- Conditions
- Hyperfibrinolysis, Cesarean Section Complications, Coagulation Defect; Bleeding, Peripartum Haemorrhage
- Trial name
- NCT05975112
- Testing
- Coagulation tests (TEG, Levels of F1, F2, hs-D-dimer, Plasminogen, PAI 1+2), SpHb before discharge
- Where
- Austria
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Immune Thrombocytopenia
Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia
In this study, we tried to demonstrate clinical benefit of additive danazol to romiplostim therapy in patients with eltrombopag-resistant immune thrombocytopenia
- Trial name
- NCT04289207
- Testing
- Romiplostim and danazol
- Volunteers
- 55 people
- Sponsor
- Seoul National University Hospital
Bone Marrow Failure Syndrome, Thalassemia
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum…
- Conditions
- Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia
- Trial name
- NCT03513328
- Testing
- Thiotepa--single daily dose, Thiotepa--escalated dose
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Haemophilia B
Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
The purpose of this study is to collect data on adverse events from third party registries that include information about adverse events from patients with haemophilia B treated with nonacog beta pegol.
- Trial name
- NCT03690336
- Testing
- Nonacog beta pegol
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 10 people
- Sponsor
- Novo Nordisk A/S
Immune Thrombocytopenia, Treatment
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
This single-arm, open-label phase II study aim to evaluate the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) combined with Rituximab in ITP patients.This study will be conducted in ITP patients who had not…
- Trial name
- NCT07362199
- Testing
- Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Congenital Bleeding Disorder, Haemophilia B
Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of the trial is to evaluate the safety and efficacy of NNC-0156-0000-0009 (nonacog beta pegol) during surgical procedures in patients…
- Trial name
- paradigm™ 3 (NCT01386528)
- Testing
- nonacog beta pegol
- Where
- 41 sites in United States, Austria and 15 more
- Volunteers
- 13 people
- Sponsor
- Novo Nordisk A/S
SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
The SABRE study is a single-arm prospective study measuring safety, tolerability and pharmacokinetics of two SARS-CoV-2 neutralising antibodies (BMS-986414 and BMS-986413) amongst high-risk special populations of vaccine…
- Conditions
- SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease, Myeloma, Leukemia
- Trial name
- SABRE (NCT05393999)
- Testing
- BMS-986414, BMS-986413
- Where
- United Kingdom
- Sponsor
- Imperial College Healthcare NHS Trust
Immune Thrombocytopenia (ITP), Treatment
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
To evaluate the efficacy and safety of CM336 in the treatment of refractory adult primary immune thrombocytopenia
- Trial name
- NCT06799611
- Testing
- CM336 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Coagulopathy
Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy
Phase 2a study to assess the safety and efficacy of IV infused spray-dried solvent/detergent -treated plasma (Resusix) when compared with an equal volume of plasma frozen within 24 hours after phlebotomy (FP24) in patients with…
- Trial name
- NCT03700723
- Testing
- Resusix, FP24 (Frozen Plasma)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Entegrion, Inc.
Pneumonia, Sepsis
Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis
Pneumonia is a lung infection that can cause serious complications, especially when accompanied by sepsis. Sepsis can trigger excessive inflammation and abnormal blood clotting, potentially leading to organ damage and delayed…
- Conditions
- Pneumonia, Sepsis, Blood Coagulation Disorders
- Trial name
- NCT07892794
- Testing
- DLBS1033
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Sebelas Maret
Effect of Postoperative Topical St. John's Wort Oil (Hypericum Perforatum) on Periorbital Edema and Ecchymosis Following Rhinoplasty
THE EFFECT OF ST. JOHN'S WORT OİL APPLİCATİON ON PERIORBITAL EDEMA AND ECCHYMOSİS AFTER RHİNOPLASTY
Rhinoplasty is one of the most frequently performed procedures in aesthetic and reconstructive surgery, with steadily increasing demand worldwide.
- Trial name
- NCT07448051
- Testing
- Topical St. John's Wort oil application
- Where
- Turkey (Türkiye)
- Volunteers
- 110 people
- Sponsor
- Inonu University
Severe Sepsis, Coagulopathy
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
- Trial name
- NCT01598831
- Testing
- ART-123
- Where
- 161 sites in United States, Argentina and 22 more
- Volunteers
- 816 people
- Sponsor
- Asahi Kasei Pharma America Corporation
Thrombocytopenia, Purpura, Thrombocytopenic
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
It is a translational research study with mechanistical objectives and including biological samples of patients with thrombocytopenia
- Conditions
- Thrombocytopenia, Purpura, Thrombocytopenic, Myelodysplastic Syndromes
- Trial name
- ICTUS (NCT04003220)
- Testing
- blood sample, Bone marrow sample
- Where
- 4 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Immune Thrombocytopenia
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.
- Trial name
- NCT04638829
- Testing
- Avatrombopag Oral Tablet
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sobi, Inc.
Anticoagulants and Bleeding Disorders, Surgery
Oral Surgery in Patients Taking Direct Oral Anticoagulants
This study evaluates the incidence of postoperative bleeding after oral surgical procedures in patients taking direct oral anticoagulants and in patients taking vitamin K antagonists.
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage, Dentoalveolar Haemorrhage
- Trial name
- OSDOA (NCT04505475)
- Testing
- Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
- Where
- Serbia
- Volunteers
- 82 people
- Sponsor
- University of Novi Sad
Immune Thrombocytopenic Purpura
Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia
The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.
- Trial name
- ITP (NCT01672151)
- Testing
- rapamycin
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Suzhou Medical College
Hemophilia A
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
This open-label, multicenter expanded access program (EAP) is designed to provide emicizumab to eligible participants with hemophilia A with factor VIII (FVIII) inhibitors before it is commercially available in the United States…
- Trial name
- NCT03154437
- Testing
- Emicizumab
- Where
- 14 sites in United States
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.